@article{5165f66a82b54490884cbcadd5ee8e30,
title = "Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer: a Brown University Oncology Group Phase II Study.",
author = "Howard Safran and Charpentier, \{Kevin P.\} and Andreas Kaubisch and Kalyan Mantripragada and Gregory Dubel and Kimberly Perez and Katherine Faricy-Anderson and Thomas Miner and Yoko Eng and Joel Victor and Angela Plette and Joseph Espat and Pamela Bakalarski and Patti Wingate and David Berz and Denise Luppe and Diane Martel and Kayla Rosati and Santiago Aparo",
note = "Purpose: To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. Materials and methods: Patients with advanced HCC who progressed on or were intolerant to sorafenib were eligible. Patients received lenalidomide 25 mg orally for 1 to 21 days in a 28-day cycle until disease progression or unacceptable toxicities.",
year = "2015",
month = jan,
day = "2",
doi = "10.1097/COC.0b013e3182868c66",
language = "American English",
volume = "38",
journal = "American Journal of Clinical Oncology",
}